The ag-biotech business ArkeaBio, situated near Boston, MA, has secured $26.5 million in Series A investment.
Investors
- AgriZeroNZ
- Rabo Ventures
- Overview Capital
- The51 Food & AgTech Fund
- The Grantham Foundation for the Protection of the EnvironmentBreakthrough Energy Ventures (BEV)
Use of funds
The funding will be used by the firm to further research, development, and vaccine rollout, including extensive field testing and supply chain involvement.
To bring this game-changing technology to market, ArkeaBio is committed to working together with industrial partners, regulatory bodies, and environmental groups.
About ArkeaBio
ArkeaBio, an ag-biotech venture led by CEO Colin South, is creating a vaccination to lower methane emissions from ruminants that will be compatible with current global agribusiness methods. With the help of the company’s vaccination, global livestock methane emissions can be decreased. At the moment, these emissions amount to 3 billion tons of CO2 annually, or 6% of total greenhouse gas emissions.
“We are thankful for the financial assistance, faith, and trust of his investors. With this support, we will be able to address an urgent worldwide issue more quickly by developing our vaccine-based solution.”
Colin South
